In Abuja, Nigeria, a significant advancement in HIV prevention has been unveiled with the official launch of Lenacapavir, a novel twice — yearly injection. This innovative treatment is poised to revolutionize the country’s HIV prevention strategy by replacing the traditional daily oral medication with a more convenient bi-annual regimen.
The launch event, themed “Flagging off the future of HIV prevention, “saw the first recipients being administered the long-acting dose, marking a substantial milestone in Nigeria’s ongoing battle against HIV/AIDS. Adedolapo Fasawe, the Mandate Secretary for Health and Environment in the Federal Capital Territory, emphasized the drug’s purpose during the event. “Lenacapavir is long-acting and is for the prevention of HIV/AIDS, “she stated, highlighting the necessity of testing negative for HIV before receiving the injection.
Fasawe also warned that the medication is ineffective for those who are already HIV — positive and could potentially be harmful.
The introduction of Lenacapavir represents a significant shift in the approach to HIV prevention, offering individuals a less frequent, yet effective, method of protection. This development aligns with the broader goals of enhancing public health and addressing the challenges associated with managing chronic diseases in Nigeria.
The article was originally published by Global South World and is republished here with permission. Global South World is dedicated to addressing the rise of influential nations outside traditional geopolitical power structures and to amplifying the voices of the Global South, raising awareness of changes and trends in those countries.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: africa
Source: SG Editor
